UPDATE ON RAPID DIAGNOSTIC TESTING FOR COVID-19

Received 2021-09-09; Accepted 2021-10-08; Published 2021-10-26

Authors

  • Jia Hui Tan Department of Parasitology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
  • Muhammad Luqman Arif Mohd Yusri Department of Parasitology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
  • Moong Yan Leong Department of Parasitology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
  • Yee Ling Lau Department of Parasitology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.

DOI:

https://doi.org/10.22452/jummec.sp2021no1.3

Keywords:

Rapid Diagnostic Test, Loop-Mediated Isothermal Amplification, Recombinase Polymerase Amplification, CRISPR

Abstract

Coronavirus 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). To date, the disease has spread globally and caused 4 million deaths worldwide. SARS-CoV-2 spreads rapidly, leading to significant impacts on healthcare systems, social disruption and economic loss. To date, real time reverse transcription polymerase chain reaction remains the gold standard for diagnosis. However, it is costly and time consuming which result in delayed treatment and isolation of infected individuals. Hence, reliable and rapid diagnostic method is required for rapid detection of SARS-CoV-2. There have been a number of COVID-19 rapid diagnostic tests developed and evaluated widely for COVID-19 diagnosis, but a number of concerns related
to these products have arisen. In this review, we provide an update on the available COVID-19 rapid diagnostic tests and discuss the feasibility and acceptability of these rapid tests for COVID-19 diagnosis. Continuous global improvement in diagnostic test is crucial for rapid detection of the infection to optimize patient management and prevent the spread of disease.

Downloads

Download data is not yet available.

Downloads

Published

2021-10-26

Issue

Special Issue Covid-19 (2021)

Section

Research article

License

All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.